English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Understanding the pathogenesis of chronic venous disease (CVD) and the clinical consequences of venous hypertension has motivated the search for successful treatments for this condition [1, 2]. The wide range of clinical presentations and patient complaints related to CVD often require complex treatments based on lifestyle modification, the use of compression stockings, pharmacotherapy, and/or surgical or other minimally invasive treatments [2]. Pharmacotherapy is an important component of CVD treatment, and a wide range of drugs is currently available [2, 3]. Despite the number of medications used and suggested for the treatment of CVD, the evidence-based confirmation of the efficacy of many of these drugs remains ABSTRACT The wide range of clinical presentations and patient complaints related to chronic venous disease often require complex treatments based on lifestyle modification, the use of compression stockings, pharmacotherapy, and/or surgical or other minimally invasive treatments. According to most available guidelines, the main indication for pharmacotherapy in patients with chronic venous disease is the presence of symptoms related to venous hypertension, including leg pain and heaviness. Additional patient complaints that are indicators for venotrophic pharmacological treatment include leg edema and venous leg ulcers. Despite these suggested indications, the clinical evidence for the benefit of many available drugs remains questionable. The paper presents an overview of the available literature on Ruscus aculeatus extract and drugs containing Ruscus extract. The current literature and a recent systematic review and meta-analysis confirm the use of Ruscus aculeatus extract as a phlebotropic drug with evidence-based confirmation of its positive effects on complaints related to chronic venous disease. The variety of possibilities for the pharmacological treatment of chronic venous disease enables pharmacological intervention using various compounds that address different mechanisms of chronic venous disease-related pathology. The current evidence concerning Ruscus aculeatus as a component of combined treatment (with hesperidin methyl chalcone and ascorbic acid) suggests the need to upgrade the position of this drug in the current CVD pharmacotherapy guidelines.

The clinical efficacy of Ruscus Aesculatus extract: is there enough evidence to update the pharmacotherapy guidelines for chronic venous disease?